Financial information


Introduction


Helix BioPharma’s financial statements and related MD&A are archived on this web site for historical purposes only. Specific information included in these documents may change over time, and may or may not be accurate after the date on the documents. Helix BioPharma has no intention and specifically disclaims any duty to update the information in these documents.

For financial information earlier than the dates listed below, please go to www.sedar.com. Security holders may obtain a hard copy of our audited financial statements free of charge from the Chief Financial Officer of the issuer, by writing to him at: 9120 Leslie Street, Suite 2015, Richmond Hill, ON, L4B 3J9, by telephone: 905-841-2300 x233, e-mail: ir@helixbiopharma.com, or fax: 905-841-2244.

Q2F2020

Press release | Helix Biopharma Corp. announces fiscal second quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1F2020

Press release | Helix Biopharma Corp. announces fiscal first quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE F2019

Press release | Helix Biopharma Corp. announces fiscal fourth quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2019


AIF | Annual Application Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix Biopharma Corp.

Q3 F2019

Press release | Helix Biopharma Corp. announces fiscal third quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 F2019

Press release | Helix Biopharma Corp. announces fiscal second quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 F2019

Press release | Helix Biopharma Corp. announces fiscal first quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE F2018

Press release | Helix Biopharma Corp. announces fiscal fourth quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2019


AIF | Annual Application Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix Biopharma Corp.

Q3 F2018

Press release | Helix Biopharma Corp. announces fiscal third quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 F2018

Press release | Helix Biopharma Corp. announces fiscal second quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 F2018

Press release | Helix Biopharma Corp. announces fiscal first quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE F2017

Press release | Helix Biopharma Corp. announces fiscal fourth quarter 2017 results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2017


AIF | Annual Application Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix Biopharma Corp.

Q3 F2017

Press release | Helix Biopharma Corp. announces fiscal third quarter 2017 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 F2017

Press release | Helix Biopharma Corp. announces fiscal second quarter 2017 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 F2017

Press release | Helix Biopharma Corp. announces fiscal first quarter 2017 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE F2016

Press release | Helix Biopharma Corp. announces fiscal fourth quarter 2016 results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2016


AIF | Annual Application Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix Biopharma Corp.

Q3 F2016

Press release | Helix Biopharma Corp. announces fiscal third quarter 2016 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 F2016

Press release | Helix Biopharma Corp. announces fiscal second quarter 2016 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 F2016

Press release | Helix Biopharma Corp. announces fiscal first quarter 2016 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE F2015

Press release | Helix Biopharma Corp. announces fiscal fourth quarter 2015 results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2015


AIF | Annual Application Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix Biopharma Corp.

Q3 F2015

Press release | Helix Biopharma Corp. announces fiscal third quarter 2015 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 F2015

Press release | Helix Biopharma Corp. announces fiscal second quarter 2015 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 F2015

Press release | Helix Biopharma Corp. announces fiscal first quarter 2015 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE F2014

Press release | Helix Biopharma Corp. announces fiscal fourth quarter 2014 results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2014


AIF | Annual Application Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix Biopharma Corp.

Q3 F2014

Press release | Helix Biopharma Corp. announces fiscal third quarter 2014 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 F2014

Press release | Helix Biopharma Corp. announces fiscal second quarter 2014 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 F2014

Press release | Helix Biopharma Corp. announces fiscal first quarter 2014 results



MD&A | Management’s discussion and analysis of financial condition and results of operations